BG Medicine Obtains CE Mark for CardioSCORE(TM) Test in Europe

BG Medicine Obtains CE Mark for CardioSCORE(TM) Test in Europe

Innovative Blood Test for the Prediction of Major Cardiovascular Events
Expected to Launch in the First Half of 2013

WALTHAM, Mass., Dec. 11, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
(Nasdaq:BGMD), a diagnostics company focused on the development and
commercialization of novel cardiovascular tests, today announced that it has
obtained a CE Mark enabling the commercial sale of the CardioSCORE™ test in
the EU and other countries that recognize the CE Mark. The CardioSCORE test is
the company's patented diagnostic blood test designed to dramatically improve
risk prediction of major cardiovascular events beyond traditional risk factor
assessments, such as the Framingham Risk Score and European SCORE.

The CardioSCORE test is performed on a standard blood sample and utilizes
algorithmic analysis to combine the results of seven reimbursed protein
assays. The test involves an independent scoring system that yields a
quantitative result ranging from 0.0 to 10.0, with higher values indicating
elevated risk for a major cardiovascular event in the subsequent 3 years and
with each 1.0 point increment representing a 30% increase in relative risk. In
the 6,600 patient BioImage Study cohort, the primary clinical validation study
for the CardioSCORE test, among those who experienced a near-term major
cardiovascular event during follow-up, only 26% were identified as being at
high risk at baseline by traditional risk factors, whereas 54% percent were
identified as being at high risk upon addition of their CardioSCORE result
(p<0.0001).

"We are thrilled to bring the benefits of the CardioSCORE test to patients and
physicians in Europe. We believe this test will be a pivotal and disruptive
game-changer in the primary prevention of major cardiovascular events and
treatment of disease, representing a major advancement over the diagnostic
tools clinicians have used for the past 15 years," said Eric Bouvier,
President and Chief Executive Officer of BG Medicine."The majority of
cardiovascular events occur among patients who are asymptomatic, and current
risk factor assessment methods simply miss too many patients with hidden
subclinical risk, delaying appropriate therapy and effective monitoring of
response to such therapy. The CardioSCORE test will identify individuals at
elevated risk for heart attack and stroke, enabling preventive
intervention.We are working aggressively to launch the test in the first half
of 2013 in Europe in collaboration with specialty laboratory partners." 

"The CardioSCORE test may have the potential to help improve the care of many
people by providing a simple, accurate and clinically meaningful score to
assess an individual's risk for near-term major cardiovascular events," said
Valentin Fuster, MD, PhD, Professor of Cardiology and Director of Mount Sinai
Heart.

Last month, investigators at the American Heart Association (AHA) Scientific
Sessions 2012 presented the results of several analyses of the CardioSCORE
test performance in the BioImage Study. The presentations by investigators
from the Mt. Sinai School of Medicine and the Baptist Hospital of Miami
highlighted the predictive value of the test in assessing risk for near-term
major cardiovascular events across a broad and diverse community-dwelling
population. A summary of these findings is available here:
http://investor.bg-medicine.com/releases.cfm.

"Obtaining the CE Mark for the CardioSCORE test is not only a significant
milestone in the prevention and treatment of cardiovascular disease but also a
critical advancement in our company's continued transformation into a
full-scale commercial organization," continued Mr. Bouvier."BG Medicine now
has two products covering the continuum of heart disease diagnostics,
positioning us strongly to drive the clinical usage of our important
diagnostic tests for millions of patients who will benefit from them
throughout the world."

The CardioSCORE test is not yet available commercially in the United
States.BG Medicine is continuing its active discussions with the US Food and
Drug Administration regarding 510(k) clearance for the test in the United
States.

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD) is a diagnostics company focused on the
development and commercialization of novel cardiovascular tests to address
significant unmet medical needs, improve patient outcomes and reduce
healthcare costs. The Company has two products: the BGM Galectin-3^® test for
use in patients with chronic heart failureis available in the United States
and Europe;and theCardioSCORE™test for the risk prediction of major
cardiovascular events will be launched in Europe in the first half of
2013.For additional information about BG Medicine, heart failure and
galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.

The BG Medicine Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=10352

Special Note Regarding Forward-looking Statements

Certain statements made in this news release contain forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities and Exchange Act of 1934, as
amended, that are intended to be covered by the "safe harbor" created by those
sections. Forward-looking statements, which are based on certain assumptions
and describe our future plans, strategies and expectations, can generally be
identified by the use of forward-looking terms such as "believe," "expect,"
"may," "will," "should," "could," "seek," "intend," "plan," "estimate,"
"anticipate" or other comparable terms. Forward-looking statements in this
news release address our belief in the significant potential of the
CardioSCORE test to provide valuable information about an individual's risk of
experiencing near-term major cardiovascular events; our belief in the
importance of receiving CE Mark in the EU in order to foster widespread
adoption of the CardioSCORE test and as a means of broadening our
commercialization efforts for our diagnostics tests generally; our belief that
there is a critical need for a simple and easy-to-use blood test to more
accurately determine patients' risks for near-term major cardiovascular
events. Forward-looking statements are based on management's current
expectations and involve inherent risks and uncertainties which could cause
actual results to differ materially from those in the forward-looking
statements, as a result of various factors including those risks and
uncertainties described in the Risk Factors and in Management's Discussion and
Analysis of Financial Condition and Results of Operations sections of our
recent filings with the Securities and Exchange Commission, including our most
recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We urge
you to consider those risks and uncertainties in evaluating our
forward-looking statements. We caution readers not to place undue reliance
upon any such forward-looking statements, which speak only as of the date
made. Except as otherwise required by the federal securities laws, we disclaim
any obligation or undertaking to publicly release any updates or revisions to
any forward-looking statement contained herein (or elsewhere) to reflect any
change in our expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based.

CONTACT: Chuck Abdalian
         EVP & Chief Financial Officer
         (781) 434-0210

BG Medicine Inc. logo